UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 23,862 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 404,667 shares of the company's stock after selling 23,862 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.62% of Kymera Therapeutics worth $16,280,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Blue Trust Inc. lifted its holdings in Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after purchasing an additional 270 shares during the period. State of Wyoming acquired a new stake in Kymera Therapeutics in the fourth quarter worth about $45,000. KBC Group NV lifted its holdings in Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after purchasing an additional 752 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Kymera Therapeutics by 95.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock worth $194,000 after purchasing an additional 2,350 shares during the period. Finally, Summit Investment Advisors Inc. lifted its holdings in Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after purchasing an additional 406 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on KYMR shares. Guggenheim reaffirmed a "buy" rating and issued a $52.00 price objective on shares of Kymera Therapeutics in a report on Monday, May 12th. HC Wainwright upped their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Stifel Nicolaus started coverage on shares of Kymera Therapeutics in a report on Tuesday, May 20th. They issued a "buy" rating and a $55.00 price target for the company. Bank of America cut their price target on shares of Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating for the company in a report on Monday, May 12th. Finally, Citigroup started coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $52.00 price target for the company. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $55.25.

Kymera Therapeutics Price Performance

NASDAQ KYMR traded down $0.79 on Friday, hitting $29.46. 649,895 shares of the company were exchanged, compared to its average volume of 568,376. The firm has a market capitalization of $1.92 billion, a P/E ratio of -12.59 and a beta of 2.18. Kymera Therapeutics, Inc. has a twelve month low of $19.45 and a twelve month high of $53.27. The company's 50 day moving average price is $28.58 and its 200-day moving average price is $35.75.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm's quarterly revenue was up 114.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.69) EPS. As a group, equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Activity

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares of the company's stock, valued at $2,064,510. This represents a 2.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at $6,147,428.70. The trade was a 3.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock worth $324,567 in the last 90 days. Company insiders own 16.01% of the company's stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.